Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$12.35
-1.04-7.77%
At close: -
$12.35
0.000.00%
After Hours: Jun 20, 4:11 PM EDT
Comments
Loading...
Cadrenal Therapeutics Analyst Ratings and Price Targets | NASDAQ:CVKD | Benzinga
Cadrenal Therapeutics Inc has a consensus price target of $18 based on the ratings of 2 analysts. The high is $32 issued by HC Wainwright & Co. on May 16, 2025. The low is $4 issued by Noble Capital Markets on December 18, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on May 16, 2025, November 11, 2024, and June 6, 2024, respectively. With an average price target of $22.33 between HC Wainwright & Co., there's an implied 80.84% upside for Cadrenal Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Noble Capital Markets
1calculated from analyst ratings
Analyst Ratings for Cadrenal Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2025 | Buy Now | 159.11% | HC Wainwright & Co. | Joseph Pantginis46% | $32 → $32 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | 159.11% | HC Wainwright & Co. | Joseph Pantginis46% | $3 → $32 | Maintains | Buy | Get Alert |
| 06/06/2024 | Buy Now | -75.71% | HC Wainwright & Co. | Joseph Pantginis46% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | -75.71% | HC Wainwright & Co. | Joseph Pantginis46% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | Buy Now | -75.71% | HC Wainwright & Co. | Joseph Pantginis46% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | Buy Now | -67.61% | Noble Capital Markets | Robert LeBoyer54% | → $4 | Initiates | → Outperform | Get Alert |
| 11/20/2023 | Buy Now | -75.71% | HC Wainwright & Co. | Joseph Pantginis46% | → $3 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Cadrenal Therapeutics (CVKD) stock?
The latest price target for Cadrenal Therapeutics (NASDAQ:CVKD) was reported by HC Wainwright & Co. on May 16, 2025. The analyst firm set a price target for $32.00 expecting CVKD to rise to within 12 months (a possible 159.11% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cadrenal Therapeutics (CVKD)?
The latest analyst rating for Cadrenal Therapeutics (NASDAQ:CVKD) was provided by HC Wainwright & Co., and Cadrenal Therapeutics reiterated their buy rating.
When was the last upgrade for Cadrenal Therapeutics (CVKD)?
There is no last upgrade for Cadrenal Therapeutics
When was the last downgrade for Cadrenal Therapeutics (CVKD)?
There is no last downgrade for Cadrenal Therapeutics.
When is the next analyst rating going to be posted or updated for Cadrenal Therapeutics (CVKD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cadrenal Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cadrenal Therapeutics was filed on May 16, 2025 so you should expect the next rating to be made available sometime around May 16, 2026.
Is the Analyst Rating Cadrenal Therapeutics (CVKD) correct?
While ratings are subjective and will change, the latest Cadrenal Therapeutics (CVKD) rating was a reiterated with a price target of $32.00 to $32.00. The current price Cadrenal Therapeutics (CVKD) is trading at is $12.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
